News|Articles|November 4, 2024
Best Practices, Strategies & Use of Novel Biological Responses for Robust Cell-Based Potency Assays
Author(s)Catalent
Cell-based assays (CBAs) are key tools for evaluating the potency of new biologic drugs. Catalent’s transcription-based bioassay simplifies and empowers the testing of new biologics.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
What Jideytro's Approval Means for Drug Developers
2
Q&A : Brent Wilhelm on Supply Chains and Historical Demand Data
3
PharmTech Weekly Roundup—July 24, 2026
4
Midyear 2026 Check-In: AI Investment Skipped Pharma's Costliest Operational Problem
5